Siren, L.L.C.
Overview
Siren, L.L.C. is a private investment firm based in New York, NY, managing a diversified portfolio across multiple asset classes and industries. The firm focuses on investments in healthcare, technology, consumer cyclical, consumer defensive, real estate, financial services, and industrials sectors. Their investment strategy encompasses various stages, including growth, late stage, pre-IPO, buyout, turnaround, and distressed investments. With a geographical focus primarily in the United States, Siren, L.L.C. seeks to deploy capital in opportunities ranging from $100 million to $1 billion. The firm's approach emphasizes strategic investments aimed at fostering growth and value creation across its portfolio companies. Their track record reflects a commitment to delivering substantial returns through a disciplined investment process and active portfolio management.
Investment Focus
- Focus on healthcare, technology, consumer cyclical, consumer defensive, real estate, financial services, and industrials sectors
- Geographical focus on the United States
- Interest in growth, late stage, pre-IPO, buyout, turnaround, and distressed investments
Portfolio Companies
Reach Siren, L.L.C. directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Siren, L.L.C.
What sectors does Siren, L.L.C. invest in?
Siren, L.L.C. invests in Financial Services, Technology, Healthcare, Industrials, Real Estate and Consumer Defensive, and is based in New York, United States. Siren, L.L.C. is listed as a private investment firm in the ConnectSafely investor database.
What stage does Siren, L.L.C. invest at?
Siren, L.L.C. backs companies at Growth, Late Stage, Pre-IPO, Buyout, Turnaround and Distressed, writing cheques of 100M - 1B.
Which regions does Siren, L.L.C. invest in?
Siren, L.L.C. invests across United States.
What companies has Siren, L.L.C. invested in?
Siren, L.L.C.'s portfolio includes Kymera Therapeutics, Inc., Scholar Rock Holding Corp, Bei Gene, Ltd., Arrowhead Pharmaceuticals, Inc. and Bicara Therapeutics Inc..
Last updated · Source: ConnectSafely investor database